Audit The Herd
CPA, Corporate Finance Professional
Lemonade and Tempus AI are where AI returns become visible, as capital moves from infrastructure up to the application layer. Big Tech's hundreds of billions in AI capex still show little attributable revenue and no clear moat beyond scale, and infrastructure depreciates. Lemonade's marketing buys customer relationships that can last decades and improve underwriting; Tempus's clinical dataset grows harder to replicate with each patient, backing pharma revenue with 126% NRR. x.comÂ
Lemonade and Tempus AI should be durable winners because they own closed, proprietary data loops rather than renting intelligence from frontier AI labs. Palantir's Alex Karp warned that replacing core workflows with closed models shifts ownership and data to OpenAI or Anthropic. Lemonade's in-house stack, trained on its own claims data, drove a record-low 62% loss ratio and more than doubled gross profit. Tempus owns oncology data from sequencing to outcomes; regulated sectors reward provenance. x.comÂ
AI's application layer remains the long-term bet: after 24 months in infrastructure on obvious earnings, capital must now move to the layer that produces durable economic value. Tempus AI's edge is proprietary data, which stays scarce as raw intelligence gets cheaper. Eli Lilly's LillyPod pairs 1,000 Blackwell GPUs with decades of clinical data, an underrated moat. Lemonade's tech yields cost, price and growth edges. Coinbase provides the stablecoin financial guardrails agentic AI needs. x.comÂ
Lemonade is light years ahead of competitors in agentic insurance as policies shift from set-and-forget to hundreds of micro-interactions each year. It is the first company to truly enter this model while incumbents still work on AI premium-pricing models. Pet insurance involves frequent small claims, and car telematics keeps updating driving-based prices and safety assessments. x.comÂ
Tempus AI is a short idea because the stock is being pumped on recent FDA clearances for its EKG-AI tools, while the revenue from them is far off and may never materialize. x.comÂ
Lemonade is one of the best buys in the market because its AI model lets it scale customers, products and revenue without scaling headcount. In-force premium grew 32% YoY, its tenth straight quarter of acceleration, and doubled over three years as headcount fell; revenue tripled while gross profit grew 10x. Up to 50% discounts for miles driven on Tesla FSD show an edge traditional insurers can't copy. It should be EBITDA profitable in Q4 2026, yet the stock fell 50% in four months. x.com x.comÂ
Lemonade's approach to building an AI-agent insurance platform could become the global standard. Building a complete way for agents to buy, renew or file claims through Lemonade OS is brilliant; the company is building for the agentic era. x.comÂ
Tempus AI's 2025 growth was less impressive than it looks: only half was organic, with the other half coming from the Ambry acquisition. x.comÂ
Better underwriting at Root, AI data demand at Innodata, defense breadth at Applied Aerospace & Defense, scaled voice AI at SoundHound, more organ access via TransMedics, profitable insurance at Lemonade, autonomous defense at Ondas and successful medicines at AbCellera could drive outsized growth. These eight smaller companies have a realistic path to 5x+ over 5-10 years if they execute on those opportunities. x.com x.com x.com x.com x.com x.com x.com x.comÂ
Tempus AI has a data moat no one has replicated: a multimodal, patient-linked genomic, clinical and imaging dataset at scale. It holds over 8 million imaging files, 1.5 million matched clinical and molecular profiles and 4.5 million sequencing samples, which drug companies leaning on AI increasingly need. It is expanding from oncology into cardiology, neuropsychiatry and radiology. Revenue grows 25% and gross margin rose from 32% in 2021 to 64%, though last quarter's profit was a one-time item. … Show more
Tempus AI is a second- or third-tier genomic lab whose AI story is marketing mumbo jumbo, and its management team are promoters. x.comÂ
Tempus AI's thesis remains intact after objectively strong earnings and a guidance raise. It looks less threatened by Anthropic than other software names because its datasets form its moat, for now. Software multiples remain a big question, and these stocks are struggling to catch a break, but the technical setup still looks good despite the pullback. x.comÂ
